Phase III trial of Tesamorelin for Non-alcoholic-steatohepatitis
Latest Information Update: 29 Oct 2024
Price :
$35 *
At a glance
- Drugs Tesamorelin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Registrational; Therapeutic Use
- 09 Oct 2024 According to Thera Technologies media release, impact of Tesamorelin on cardiovascular disease risk prediction scores in Phase 3 Studies treatment arms: Subanalysis, will be presented in a poster session at IDWeek 2024, on Thursday, October 17, 2024, 12:15 PM -1:30 PM PT.
- 24 Mar 2021 New trial record